About Taiwan Mitochondrion Applied Technology Co.,Ltd

With the arrival of an aging society, numerous studies in the past decade have shown that mitochondria are closely related to aging and degenerative diseases such as Parkinson's and Alzheimer's disease. This is because when mitochondrial function is abnormal, it can lead to insufficient energy supply and oxidative stress, even inducing cell apoptosis or autophagy, which in turn leads to the onset of diseases.

Top 10 Biotech Innovation Companies in the Asia-Pacific Region

The mitochondrial activation products developed by Taiwan Mitochondrion are not a biotechnology gimmick. These products not only offer new anti-aging and disease treatment solutions through mitochondrial reconstruction technology (MRT), but they can also directly rebuild the mitochondrial function of cells, making it undoubtedly one of the most innovative technologies. Dr. Zheng Hanzhong, the founder of the company, stated, 〝We believe that mitochondria are the key to revitalization and disease treatment, which is why we have not only established a mitochondrial reconstruction technology platform, but also offer high-quality mitochondrial activation products.〞 Therefore, the related products developed by Taiwan Mitochondrion have actual effects rather than being a mere gimmick. By viewing the certified recognition from foreign professional journals as one of the Top 10 Biotech Innovation Companies in the Asia-Pacific Region, you can find out the authenticity, the technology of activating mitochondria is not only the rising star of regenerative medicine but has also been practically applied in today's black technology products.

Product Development Recognized for International Quality Assessment

Established in March 2014, Taiwan Mitochondrion is chaired by founder Dr. Han-Chung Zheng. He leads a team of academic and industry professionals in the development and engineering application of mitochondrial technology platforms. They have established a mitochondrial analysis (precision medicine) technology platform and a biotech new drug development/processing (cell therapy) technology platform, and built a GTP-grade clinical cell factory. By integrating clinical application needs and product development technologies, they develop forward-looking mitochondrial medical products for clinical treatment.

The award-winning products of Monde Selection were developed and commercialized using the two technology platforms mentioned above. By designing the award-winning products from the perspective of precision medicine and cell therapy, these products can accurately enhance the activity of aging mitochondria in the body, restore cellular function, and delay aging and prevent diseases. Taiwan Mitochondrion is currently working on projects related to the treatment of Parkinson's disease and infertility, and has received government funding and international patent protection. The therapeutic effects on Parkinson's disease are better than general stem cells, promoting more regeneration of dopamine neurons.

Chairman Dr. Han-Chung Zheng of Taiwan Mitochondrion stated that they are currently collaborating with Hualien Tzu Chi Hospital on 'clinical trials for the treatment of Parkinson's disease.' They hope to truly help Parkinson's patients in the future and alleviate their suffering. (Reference source:「Hualien Tzu Chi Hospital official website【Pioneering new medical technologies, Taiwan Mitochondrion joins hands to reach new milestones】, the text and subtitles have been edited)

About Taiwan Mitochondrion Applied Technology Co.,Ltd

Taiwan Mitochondrion Applied Technology Co.,Ltd. is a global leader in regenerative medicine based on mitochondrial medical technology applications. It has been engaged in research and operations since 2014 and was the first to propose Mitochondrial Reconstruction Technology. The company has developed a platform for mitochondrial research and engineering application technology.

The company has been developed several product lines, including Mito Energy, Mito Peptide and Mitoslim Coffee, etc. Mitocell, Mitobio and MAKCell are all preparing to enter the next stage of clinical development. These products have proven their safety in preliminary studies. and effectiveness.

The picture below is co-authored by the founders Dr. Han-Chung Zheng and Dr. Kai-Xiang Wang《Exploring the Source of Life Energy: The Secrets of Mitochondria, the Cell Powerhouse.》

International certifications in the field of mitochondrial research

As the variety of mitochondrial products on the market increases, it is important to carefully select those with proven effectiveness. It's not just about boasting; Taiwan Mitochondria has the only internationally certified mitochondrial function analysis testing laboratory in Taiwan, indicating a clear commitment to mitochondrial research and development. Below are the relevant international certifications currently obtained by Taiwan Mitochondrion.

Mitochondrial Function Analysis Testing Laboratory International Certification (TAF 3232)

Mitochondrial Activation Stem Cell Processing Technology Service International Certification (ISO 9001:2015 TW17/01195)

Innovative Biotechnology New Drug Research Project (Taiwan Ministry of Economic Affairs, Patent No. 10620421210)

Clinical treatment of respiratory failure caused by pneumonia (Taiwan Ministry of Health and Welfare, License No. 1071607819)

Cell Therapy GTP Inspection (Taiwan Ministry of Health and Welfare, License No. 1071106719)

Phase I Open-label Dose-escalation Trial to Evaluate the Safety, Tolerability, and Efficacy of MitoCell Transplantation in Subjects with Primary Parkinson's Disease (IRB 107-205-A)

International Quality Awards Gold and Silver Medals (Monde Selection 2017, 2018, 2019)

International High-Quality Trophy (Monde Selection 2019)

Words from the founder, Dr. Han-Chong Cheng.

Mitochondria were discovered in cells as early as 1857, and their critical role in cellular energy supply was proven in the 1920s and 1930s. This research earned a Nobel Prize in Physiology or Medicine in 1931 and a Nobel Prize in Chemistry in 1997. Therefore, mitochondria, alongside stem cells, have become vital tools in modern medical research for anti-aging and combating degenerative and injury-related diseases. Mitochondria are seen as the next generation of new regenerative medicine technologies, and it is believed that their clinical applications will become more widespread in the future, leading to new trends in regenerative medicine therapies.

Our mission is to become the world's leading and most advanced provider of professional mitochondrial technology, raw materials, and manufacturing. We aim to form a strong competitive team together with our medical institutions and clientele, and serve as a long-term and reliable provider of technology and production capacity in the global regenerative medicine industry.

Company History and Evolution

• 2014.03 – Approved the establishment of Taiwan Mitochondrion Applied Technology Co.,Ltd.
• 2014.05 – Entrusted National Chung Hsing University in Taiwan to verify the 「protective effect of mitochondria on Parkinson's disease」
• 2014.06 – Entrusted China Medical University in Taiwan to verify the 「efficacy of stem cells in treating Parkinson's disease」
• 2015.01 – Passed the counseling of Taiwan Executive Yuan's National Development Fund Entrepreneurship Angel Program
• 2015.03 – Settled in the Hsinchu Biomedical Park Industry and Incubation Center of the Small and Medium Enterprises Division of the Ministry of Economic Affairs of Taiwan
• 2015.05 – Passed the counseling of the Entrepreneurship A+ Action Plan of the Small and Medium Enterprises Division of the Ministry of Economic Affairs of Taiwan
• 2015.07 – Commissioned Taiwan Mackay Medical College to conduct「Analysis Project of Mitochondria Function of Adipose Mesenchymal Stem Cells at Different Differentiation Stages」
• 2016.03 – Won the Taiwan Ministry of Economic Affairs Enterprise Innovation R&D Program Grant「Development and Safety Assessment of Cell Therapy Preparations for Parkinson's Disease」
• 2016.10 – 「Taiwan Mitochondrian Function Analysis and Testing Laboratory」passed TAF/ISO 17025 international certification
• 2016.11 – Received a subsidy from the Ministry of Science and Technology of Taiwan and cooperated with National Chung Hsing University to「use autologous mitochondria to treat infertility caused by aging」
• 2017.03 – Won the Taiwan Ministry of Economic Affairs Enterprise Innovation R&D Program Grant「Preclinical Trial of Cell Therapy Products for Parkinson's Disease」
• 2017.05 – Won the 2017 Monde Selection Gold Medal Award
• 2017.05 – Received subsidy from Taiwan's Ministry of Science and Technology and collaborated with Chung Shan Medical University on「Developing Precision Medicine for Treating Infertility Due to Aging and Mitochondrial Abnormalities」
• 2017.11 – 「Mitochondrial Activation Stem Cell Processing Technology Service」passed ISO 9001:2015 international certification
• 2019.06 – Mitochondrial activation foods participated in the Monde Selection and received international gold medal recognition. After receiving gold medal recognition for three consecutive years, we were invited to Rome to receive a crystal trophy
• 2020.07 – Taiwan's Ministry of Health and Welfare approved the registration for the phase I clinical trial of「Mitocell Stem Cell Preparations」
• 2020.08 – With the「Dynamito MAPEs Plant Extracts Development Program」successfully connected upstream, midstream, and downstream industries, and was selected as an outstanding cultivated company by the Taiwan Agricultural Technology Research Institute
• 2020.11 – Mitochondrial Activation Factor (MAPEs) achieved halal certification
• 2021.07 – Recognized by an international journal as one of the「Top 10 Biotech Innovation Companies in the Asia-Pacific Region」